REMUS PHARMACEUTICALS L (REMUS) reported revenue of ₹273 Cr and net profit of ₹19.00 Cr for the quarter ended 2024-09-30. Figures are parsed from the company's filed results.
The statements below are read from REMUS PHARMACEUTICALS L’s filed results, 3 filed quarters and 3 fiscal years on record, consolidated basis. Price-linked ratios are computed at the last close, sector medians across the served universe, ownership from the shareholding pattern, and any cell whose input isn’t on record shows a dash, never an estimate.
Latest: Q2 FY24-25 · filed Jul 24, 2026
This company files half-yearly statements with the exchange — each column is a six-month period; discrete quarterly figures are not published.
| ₹ Cr | Sep2023 | Mar2024 | Sep2024Latest | YoYlatest |
|---|---|---|---|---|
| Sales | 29.0 | 185 | 273 | n/m |
| Expenses | 20.0 | 165 | 252 | n/m |
| Operating profit | 9.00 | 20.0 | 21.0 | +133.3% |
| OPM % | 31.0% | 10.8% | 7.7% | -23.3 pp |
| Other income | 2.00 | 3.00 | 3.00 | +50.0% |
| Interest | 0.00 | 0.00 | 1.00 | — |
| Depreciation | 0.00 | 1.00 | 0.00 | — |
| Profit before tax | 10.0 | 22.0 | 22.0 | +120.0% |
| Tax % | 40.0% | 13.6% | 13.6% | -26.4 pp |
| Net profit | 6.00 | 19.0 | 19.0 | +216.7% |
| EPS (₹) | 4.87 | 13.16 | 11.87 | +143.7% |
No results filing with a recorded time yet — reactions appear from the first quarter whose announcement we timestamped (May 2026 onward), on the session the market could trade it.
